Results of Phase Ib/II study of ricolinostat in multiple myeloma
How services outside of primary and secondary care settings can help cancer patient’s treatment
Overcoming the limits: bringing CAR T-cell therapy to the masses
Can CAR T-cells be optimised to safely treat MM patients?
Why daratumumab will become key for the treatment of multiple myeloma